The reconsideration of the PET National Coverage Decision (NCD) by the Centers for Medicare & Medicaid Services (CMS) is now open for public comment.
The formal request from the National Oncologic PET Registry (NOPR) is to remove the current prospective data collection requirements as required for FDG PET used in the diagnosis, staging, restaging and monitoring response to treatment for brain, cervical, ovarian, pancreatic, small cell lung and testicular cancers, as well as for cancer indications not previously specified in Section 220.6 of the NCD manual.
Providers and referring physicians who use PET to diagnose non-covered cancers are encouraged to provide input to CMS.
The public comment period is open through May 10. Comments can be submitted here.